|Day Low/High||5.83 / 6.38|
|52 Wk Low/High||2.97 / 48.60|
Four of Five Proposals Approved at Company's 2016 Special Stockholder Meeting
StemCells (STEM) CEO Ian Massey and CFO Gregory Schiffman announced their resignations as the company announced its planned merger with Microbot Medical.
StemCells (STEM) said in an SEC filing that it will accept warrant exercises from shareholders to purchase common stock at a reduced price.
Worries over the next rate hike superseded joy over the four-day rally in crude oil, sending stocks into the red and away from their record highs.
StemCells (STEM) has announced a merger with Microbot Medical to develop robotics-based medical devices.
Companies Plan to Pursue Development of Robotics Based Medical Devices for the Treatment of Cerebrospinal Fluid and Gastrointestinal Disorders, as Well as Other Conditions
Company to Commence Orderly Wind Down of Operations
Final Results for the First Six Patients to be Released Later this Quarter
Conference Call to be Hosted March 24, 2016, at 5:00 a.m. Pacific Daylight Time (8:00 a.m. Eastern Daylight Time)
Experienced Biotech Leader to Become Next Chief Executive Officer
Management Will Present an Update on the Company's Programs, Pipeline and Operations
Prioritizes Spinal Cord Injury Program to Reduce Cash Needs and Expedite Progress to Pivotal Data
Positive Six-Month Results, With Gains in Both Strength and Motor Function, for the First Cohort in the Phase II Pathway Study
These under-$10 biotech stocks are within range of triggering breakout trades.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.